as of 11-11-2026 3:53pm EST
Iambic Therapeutics Inc is a technology and clinical-stage life sciences company developing novel medicines using its proprietary molecular superintelligence platform.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 683.0M | IPO Year: | 2026 |
| Target Price: | $24.67 | AVG Volume (30 days): | 648.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $9.60 - $24.49 | Next Earning Date: | 11-23-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 225.8% | Revenue Growth (next year): | 150.81% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Director
Avg Cost/Share
$16.00
Shares
718,750
Total Value
$11,500,000.00
Owned After
2,588,248
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Rachlin Evan Lockwood | IAM | Director | Oct 16, 2026 | Buy | $16.00 | 718,750 | $11,500,000.00 | 2,588,248 |
See how IAM stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "IAM Iambic Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.